To the best of our knowledge, the above evidence-based scheme is for the first time proposed toward understanding the pathogenesis of IPF, as well as to provide therapeutic potential of antioxidant and MAPK/Notch3 inhibitors in combination. This evidence concerns the gene NOTCH3 and idiopathic pulmonary fibrosis.